Filing Flows › Comparisons › TBPH vs LAB
Theravance Biopharma vs Standard Biotools: TBPH and LAB compared
Theravance Biopharma is the larger company: $20.7M of revenue in its latest quarter (Q2 2026) against $19.4M for Standard Biotools (Q3 2026). Standard Biotools is growing faster (-0.9% against -21% a year earlier). Theravance Biopharma is more profitable, with an operating margin of -39.9% against -102.0%.
Where the money goes: TBPH and LAB
Theravance Biopharma (TBPH) · Q2 2026
Theravance Biopharma, Q2 2026: revenue $20.7M (-21% year over year), operating margin -39.9%, net loss $5.9M, operating cash flow −$7.0M. The chart follows the revenue to costs, profit and cash.
Standard Biotools (LAB) · Q3 2026
Standard Biotools, Q3 2026: revenue $19.4M (-0.9% year over year), operating margin -102.0%, net earnings $13.5M, operating cash flow −$6.2M. The chart follows the revenue to costs, profit and cash.
| Theravance Biopharma (TBPH) | Standard Biotools (LAB) | |
|---|---|---|
| Latest quarter | Q2 2026 | Q3 2026 |
| Revenue | $20.7M | $19.4M |
| Revenue growth, Y/Y | -21% | -0.9% |
| Operating margin | -39.9% | -102.0% |
| Net earnings | −$5.9M | $13.5M |
| Net margin | -28.5% | 69.6% |
| Operating cash flow | −$7.0M | −$6.2M |
Where the revenue comes from
Standard Biotools
- Product: $14.3M (74%)
- Services and Other Revenue: $5.1M (26%)
Questions
Which is bigger, Theravance Biopharma or Standard Biotools?
Theravance Biopharma is the larger company: $20.7M of revenue in its latest quarter (Q2 2026) against $19.4M for Standard Biotools (Q3 2026).
Is Theravance Biopharma or Standard Biotools growing faster?
Standard Biotools is growing faster (-0.9% against -21% a year earlier).
Which is more profitable, Theravance Biopharma or Standard Biotools?
Theravance Biopharma is more profitable, with an operating margin of -39.9% against -102.0%.
More: Theravance Biopharma earnings · how Theravance Biopharma makes money · Standard Biotools earnings · how Standard Biotools makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 11, 2026; 10-Q filed Nov 3, 2026). Fiscal quarters can end on different dates. Not investment advice.